PD-1-binding molecules and methods of use thereof
The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.
1. An anti-human PD-1 monospecific monoclonal antibody, monospecific chimeric antibody or monospecific humanized antibody, comprising a Heavy Chain Variable Domain and a Light Chain Variable Domain, wherein:
(A) the Heavy Chain Variable Domain comprises a CDR H 1 Domain, a CDR H 2 Domain and a CDR H 3 Domain, and the Light Chain Variable Domain comprises a CDR L 1 Domain, a CDR L 2 Domain, and a CDR L 3 Domain, wherein:
(B) the CDR H 1 Domain, CDR H 2 Domain, and CDR H 3 Domain are the Heavy Chain CDRs of hPD-1 mAb 7(1.2), and respectively have the amino acid sequences: SEQ ID NO:139, SEQ ID NO:140, and SEQ ID NO:141; and
(C) the CDR L 1 Domain, CDR L 2 Domain, and CDR L 3 Domain are the Light Chain CDRs of hPD-1 mAb 7(1.2), and, respectively have the amino acid sequences: SEQ ID NO:157, SEQ ID NO:145, and SEQ ID NO:146.
2. The anti-human PD-1 monospecific antibody of claim 1 , wherein the Heavy Chain Variable Domain comprises the amino acid sequence set forth in SEQ ID NO:147.
3. The anti-human PD-1 monospecific antibody of claim 1 , wherein the Light Chain Variable Domain comprises the amino acid sequence set forth in SEQ ID NO:153.
4. The anti-human PD-1 monospecific antibody of claim 1 , wherein the Heavy Chain Variable Domain comprises the amino acid sequence set forth in SEQ ID NO:147 and the Light Chain Variable Domain comprises the amino acid sequence set forth in SEQ ID NO:153.
5. The anti-human PD-1 monospecific antibody of claim 1 , wherein:
(A) the antibody comprises an Fc Region that is of the IgG1, IgG2, IgG3, or IgG4 isotype; and
(B) when the Fc Region is of the IgG4 isotype, the antibody comprises a Hinge Domain of the IgG4 isotype that comprises a stabilizing mutation.
6. The anti-human PD-1 monospecific antibody of claim 1 , wherein the antibody comprises a variant Fc Region that comprises:
(A) one or more amino acid modifications that reduce the affinity of the variant Fc Region for an FcγR, wherein the one or more modifications that reduce the affinity of the variant Fc Region for an FcγR comprise the substitution of L234A; L235A; or L234A and L235A, and wherein the numbering is that of the EU index as in Kabat; and/or
(b) one or more amino acid modifications that enhance the serum half-life of the variant Fc Region, wherein the one or more modifications that enhance the serum half-life of the variant Fc Region comprise the substitution of M252Y; M252Y and S254T; M252Y and T256E; M252Y, S254T and T256E; or K288D and H435K, and wherein the numbering is that of the EU index as in Kabat.
7. The anti-human PD-1 monospecific antibody of claim 1 , wherein the antibody comprises an Fc Region that is of the IgG1 type.
8. The anti-human PD-1 monospecific antibody of claim 1 , wherein the antibody comprises SEQ ID NO:264 and SEQ ID NO:265.
9. The anti-human PD-1 monospecific antibody of claim 1 , wherein:
(a) the antibody comprises an Fc Region and a Hinge Domain;
(b) the Fc Region and the Hinge Domain are of the IgG4 type; and
(c) the Hinge Domain comprises a stabilizing mutation.
10. The anti-human PD-1 monospecific antibody of claim 1 , wherein the antibody comprises SEQ ID NO:264 and SEQ ID NO:266.